Acurx Pharmaceuticals, Inc.

NasdaqCM:ACXP Stock Report

Market Cap: US$26.2m

Acurx Pharmaceuticals Dividend

Dividend criteria checks 0/6

Acurx Pharmaceuticals does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.9%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$0.93
Dividend yield forecast in 3Yn/a

Recent dividend updates

No updates

Recent updates

Acurx Sell-Off Presents Opportunity Before Upcoming Data Release

Jan 22

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Oct 30
Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?

Jul 15
Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?

Mar 04
Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Nov 16
Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Acurx, Pharmaceuticals drops 8.8%, announces $4.25M direct offering

Jul 25

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

May 13
Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Jan 22
Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth

Sep 30
Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth

New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers

Aug 27

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ACXP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACXP's dividend payments have been increasing.


Dividend Yield vs Market

Acurx Pharmaceuticals Dividend Yield vs Market
How does ACXP dividend yield compare to the market?
SegmentDividend Yield
Company (ACXP)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.9%
Industry Average (Biotechs)2.9%
Analyst forecast in 3 Years (ACXP)n/a

Notable Dividend: Unable to evaluate ACXP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ACXP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ACXP's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ACXP has not reported any payouts.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.